Articles tagged with Blood Cancer
Researchers at Cold Spring Harbor Laboratory discovered that the IDH2 and SRSF2 gene mutations work together to cause acute myeloid leukemia (AML), a deadly blood cancer. The team found that the presence of these mutations leads to errors in RNA splicing, resulting in defective blood cells.
Biomedical engineer Tara Deans receives $1.5 million grant to develop alternative platelets that can help stop tumor cells from spreading in the bloodstream. Her lab will engineer platelets with proteins that kill cancer cells, inspired by her friend's diagnosis with blood cancer.
A new blood test has been developed to detect multiple types of cancer, including hormone receptor-negative breast, colorectal, and pancreatic cancer, with a high degree of accuracy. The test uses next-generation sequencing technology to probe DNA for methylation patterns associated with cancer.
New research from the University of South Australia shows that bowel cancer screening significantly reduces deaths. A study of 12,906 patients found that faecal occult blood testing and colonoscopies can catch the disease early, preventing 45% of cancer deaths.
Researchers found that methotrexate significantly reduces symptoms associated with polycythemia vera and essential thrombocythemia, two types of blood cancer. The study suggests MTX could provide low-cost, safe, and effective treatment for patients suffering from these conditions.
Researchers found that high blood sugar levels in diabetes can cause DNA damage and reduce its repair, increasing the risk of certain cancers. The study suggests that controlling blood sugar levels could be an effective way to reduce cancer risk in diabetics.
Research found raised risks of blood clots, cardiomyopathy, and heart failure among cancer survivors, particularly those treated with chemotherapy. Long-term cardiovascular risks were elevated for over five years after diagnosis.
New data from the largest population study to date reveal that having a family member with blood cancer significantly raises an individual's risk of diagnosis. The study found increased risks for certain hematologic malignancies, with the highest relative risks observed in specific subtypes of Hodgkin lymphoma and mantle cell lymphoma.
Research at the University of Sussex identified how genetic variations in two main EBV strains impact their behavior in infecting white blood cells. These differences affect the virus's ability to drive rapid cell growth, a key factor in the development of lymphoma.
Researchers at Brigham and Women's Hospital have developed a test for early detection of diseases, including different types of cancer, using sensory nanoparticles. The test can identify unique
A new approach detects mutations across many different types of normal cells by analyzing RNA sequencing data from normal tissues. The study found that 95% of individuals had at least one tissue with mutations, with higher rates in lung, esophagus, and sun-exposed skin.
A study found that slower walking speeds are linked to lower survival rates and increased likelihood of hospitalization in older patients with blood cancers. Measuring gait speed offers a useful tool for tailoring care to individual patients.
A study published in Blood found that slower walking pace is strongly associated with poorer outcomes in older adults with blood cancers. Gait speed was found to be an independent predictor of death even after adjusting for other factors, highlighting its potential as a tool to tailor care.
A large cohort study found that blood transfusion during curative liver cancer surgery increases the risk of cancer recurrence by 23% and death by 55%. The extent to which blood transfusions worsen cancer outcomes is poorly understood.
A pioneering blood test developed by Johns Hopkins researchers, CancerSEEK, will be developed by Thrive.EarlyDetection Corp. to detect multiple cancer types at earlier stages. The technology has received Breakthrough Device designation from the FDA and has shown high specificity and sensitivity in detecting various cancers.
A new blood test, DELFI, uses machine learning to identify abnormal DNA patterns in the bloodstream for early cancer detection. The test detected cancer DNA in 57-99% of patients with various stages of breast, colorectal, and other cancers.
A study published in JNCI has identified hnRNP K as an oncogene that may cause B-cell lymphomas. The overexpression of this tumour suppressor gene was found to promote the development of cancer, leading to poor recovery and low survival rates for patients.
A study of over 19,000 people found that women with obstructive sleep apnea are more likely to be diagnosed with cancer than men. The research, published in the European Respiratory Journal, suggests that women with severe OSA and low blood oxygen levels during sleep may be at greater risk of developing cancer.
Researchers at Karolinska Institutet have found that IL-1 inhibitors can reduce chronic inflammation in blood vessels exposed to radiation, which is linked to increased risk of cardiovascular disease. The study used an animal model and gene expression analysis to support the potential treatment.
Researchers have discovered a protein, YTHDF2, that plays a key role in acute myeloid leukaemia (AML), but not in healthy blood cells. This discovery holds promise for novel treatments with fewer side effects than current chemotherapy.
A risk model has been devised by Dana-Farber Cancer Institute researchers to classify patients with asymptomatic Waldenström macroglobulinemia into low, intermediate, or high risk of developing symptomatic disease. The model uses four biomarkers and was validated on two external cohorts with high accuracy and precision.
Researchers developed a mouse model to investigate the role of persistent CD30 signaling in blood cancer development. They found that permanent CD30 activation increases the risk of B-cell lymphoma and can trigger cancer through misdirected cellular processes.
A study has shown that dogs can detect cancer in blood samples with nearly 97 percent accuracy, using their highly evolved sense of smell. The research could lead to new, inexpensive ways to detect cancer without being invasive.
A prototype wearable device can continuously collect live cancer cells directly from a patient's blood, offering a biopsy alternative. This innovation could help doctors diagnose and treat cancer more effectively by providing better information for planning treatments.
Researchers at Tohoku University developed a new imaging technique to detect tumors in lymph nodes before they grow too large. The technique uses x-ray microcomputed tomography (micro-CT) and contrast agents to map the movement of cancer cells within the lymphatic system.
Researchers developed a new blood test that can identify individual molecules in human blood samples with minimal detection errors, including rare cancer-associated proteins like mutant p53 and PD-L1. This breakthrough enables accurate disease diagnosis and novel insights into cancer mechanisms.
Researchers developed a microfluidic device that can isolate individual cancer cells from patient blood samples using size separation. The device has high efficiency and reliability, with recovery rates of up to 93% for small-cell-lung cancer cells.
Researchers have cataloged circular RNA in multiple cancers and identified it as a potential biomarker for diagnosis and prognosis. The stable structure of circRNA makes it an ideal candidate for detecting cancer in blood or urine samples.
Researchers discover microRNAs miR-146a and miR-146b play crucial role in suppressing NF-κB activation, which leads to excessive cell cycle progression and rapid tumorigenesis. The study found differences in cancer outcomes depending on the absent microRNA, offering new insights into cancer development.
Researchers at Lund University have mapped the maturation process of natural killer cells, which play a key role in fighting cancer and infections. The study found that Notch signaling is essential for NK cell development and function, highlighting its potential as a target for immunotherapies.
Researchers at Duke University Medical Center have developed a technique to expand umbilical cord blood stem cells, which appears safe and restores blood count recovery faster than standard cord blood transplant in adults with blood cancer.
Researchers have developed a technique to isolate circulating tumor cells from blood, allowing for the analysis of protein makeup without biopsies. This could lead to more effective therapies and better patient outcomes by monitoring treatment progress remotely.
Researchers have developed a blood test that can detect and classify cancer at its earliest stages by analyzing epigenetic alterations. The approach holds promise of detecting cancer long before symptoms appear, making it easier to treat.
Researchers at Dana-Farber Cancer Institute have discovered a previously unknown molecular vulnerability in two rare, aggressive cancer types, synovial sarcoma and malignant rhabdoid tumors. The study identifies the ncBAF complex as a key player in these cancers' proliferation and growth.
Researchers are investigating the link between blood clots and pancreatic tumors, which could lead to more effective treatments for patients with pancreatic cancer. The study aims to understand how blood clots form and contribute to tumor growth, potentially leading to new therapeutic approaches.
Researchers developed a new combination treatment that flips the switch on melanoma cells by targeting Bcl-2, MCL-1, and DRP-1 proteins. The approach killed melanoma cells and cancer stem cells in laboratory tests, offering an alternative option for patients who don't respond to current treatments.
A highly sensitive liquid biopsy test detects minute traces of cancer-specific DNA, accurately determining whether HPV+ oral cancer patients are free from cancer following radiation therapy. The test reduces the need for costly radiological studies and provides a more precise count of tumor DNA in the blood.
Researchers at the University of Bradford have developed a universal blood test that can detect cancer in patients under suspicion of the disease with high accuracy. The test measures DNA damage caused by ultraviolet light and uses Artificial Intelligence to analyze thousands of cells, improving predictability beyond 93%.
Researchers developed a method to make personalized predictions of future disease outcomes for patients with myeloproliferative neoplasms. By combining genetic and clinical information, the study identified eight different genetic subgroups that link to patterns of clinical disease and patient prognosis.
A new study warns that HLH diagnoses can hide underlying malignancies, leading to delayed curative therapy for cancers. Researchers recommend using alternative diagnostic techniques to identify cancer prior to administering HLH therapy.
A team of researchers from St. Jude Children's Research Hospital and UNC Lineberger Comprehensive Cancer Center made important discoveries about the genetics of mixed phenotype acute leukemia (MPAL), a rare blood cancer with features of both myeloid and acute lymphoblastic leukemia.
A team of researchers at La Jolla Institute for Immunology has identified a previously unknown progenitor population with neutrophil characteristics, which promotes tumor growth. The discovery could serve as an early warning sign for cancer and drive new therapeutic approaches for treating neutropenia, chronic inflammation, and cancer.
Researchers at the University of Copenhagen have developed a new method to diagnose cancer at its early stages using a malaria protein. The method retrieves individual cancer cells from blood samples, catching them in greater numbers than existing methods, allowing for earlier detection and improved treatment outcomes.
Researchers found a simple combination of two blood tests can diagnose myeloma in GPs, enabling earlier diagnosis and treatment. The study analyzed over 2,700 cases and suggested integrating a system to alert clinicians to relevant symptoms or changes in blood parameters.
Researchers developed QPOP, a computational platform that identifies effective drug combinations against bortezomib-resistant MM. The platform successfully predicted dosages for combination therapies, leading to reduced tumor size and prolonged survival in mouse models.
Research found that invisible stool blood is associated with a heightened risk of death from bowel cancer, as well as circulatory, respiratory, digestive, and hormone diseases. A positive faecal occult blood test result was linked to an 8-fold increased risk of bowel cancer mortality.
A new technique detects mutations that affect large chunks of chromosomes in people with clonal hematopoiesis, a condition associated with substantially increased blood cancer risk. The study identified specific events that drive this increase in risk and suggests promising directions for future work.
A new report calls for better evaluation of side effects from modern blood cancer treatments, which have dramatically improved survival rates. The Commission proposes new approaches to reporting adverse events, including capturing chronic and cumulative effects.
A new clinical trial analysis found that combining an aromatase inhibitor with ovarian function suppression yields a 10-15% improvement in freedom from distant recurrence for high-risk younger breast cancer patients. Women at low risk saw minimal benefit, while those at intermediate risk gained a 4-5% advantage.
Researchers at Dana-Farber Cancer Institute have developed a blood test that can detect early-stage lung cancer using genome sequencing. The test, which analyzes free-floating DNA in the blood, has shown promise in detecting lung cancer with a low rate of false positives.
Scientists have engineered new anti-cancer antibodies that attract killer T cells directly to cancer cells covered with the ROR1 protein. These bi-specific antibodies can target several types of cancer and work for about five days, outlasting current approaches.
A new diagnostic test developed by researchers at UC San Diego shows promise for detecting pancreatic cancer earlier. The test uses electronic chip-based system to extract exosomes directly from blood, providing results in less than an hour. The findings have the potential to detect cancer early on without invasive surgical procedures.
Researchers found that most oncologists discuss medical marijuana with patients and nearly half recommend it, but only 30% feel knowledgeable enough to make recommendations. The study suggests a discrepancy between attitudes and practices regarding medical marijuana's utility in oncology.
Researchers have identified human-specific cancers that differ from animal counterparts, suggesting potential evolutionary origins. The study reveals cancer patterns in humans vary significantly from those of other species, highlighting the need for further investigation into the evolutionary underpinnings of cancer.
A study published in Circulation found that patients with acute thrombosis in the leg are at a three-fold higher risk of developing cancer during the first six months after the blood clot. The risk is highest for smoking-related forms of cancer, such as lung and pancreatic cancer.
The BIABooster device characterizes DNA in blood circulation with new precision and sensitivity, identifying promising signatures for cancer monitoring. It has been shown to detect DNA up to a concentration of 10 fg/μL with precisions of 20% and 3%.
Researchers at Johns Hopkins Medicine have developed a non-invasive test called UroSEEK, which uses urine samples to detect DNA mutations associated with bladder cancer. The test significantly enhances early detection for patients at risk and surveillance of those who have already been treated. When combined with cytology, the sensitiv...
Researchers at WashU Medicine used CRISPR to engineer human T cells that can attack human T cell cancers without succumbing to friendly fire. The new approach also allows for the use of therapeutic T cells from any healthy donor, eliminating the need for a matched donor or patient's own T cells.
Researchers at UT Southwestern's Simmons Cancer Center have made a historic breakthrough in CAR-T therapy for acute lymphoblastic leukemia (ALL) in children and young adults. Eighty-one percent of patients treated with CAR-T therapy went into remission, offering new hope for those previously untreatable.
The CancerSEEK test is a noninvasive, multianalyte test that evaluates levels of eight cancer proteins and the presence of cancer gene mutations in the blood. The test has greater than 99% specificity for cancer and can identify the location of tumors with high accuracy.